ENTITY
Oneness Biotech

Oneness Biotech (4743 TT)

21
Analysis
Health CareTaiwan
Oneness Biotech Co Ltd develops botanical new drugs and several biological-active new chemical entities that are purified and molecularly modified from these botanical sources.
more
bullishOneness Biotech
23 Jul 2024 09:30

Oneness Biotech (4743 TT): Marketing Progress of Fespixon in China Opens a New Revenue Stream

​Oneness Biotech partners with CR Double Crane for exclusive commercialization of Fespixon in China, Hong Kong, and Macau. Fespixon is approved in...

Logo
319 Views
Share
10 Nov 2024 07:30

APAC Healthcare Weekly (Nov 10)- Alteogen, Santen Pharmaceutical, Beigene, Sun Pharmaceutical

​Alteogen partners with Daiichi Sankyo for Enhertu, Volpara secures $7.3M contract, Santen launches Rhopressa in South Korea, Sun Pharma's Leqselvi...

Logo
598 Views
Share
bullishOneness Biotech
14 May 2023 23:49

Oneness Biotech (4743 TT): Global Expansion of Marketed Product & Pipeline Progress

Fespixon got approvals for Taiwan and Singapore markets. Bonvadis as a medical device for wound management has been granted market approvals in US,...

Logo
305 Views
Share
bullishOneness Biotech
30 Aug 2022 16:23

Oneness Biotech (4743 TT): Positive Clinical Trial Progress Is Pushing Stock Prices to Higher Highs

Oneness submitted an IND application to the FDA for a phase 1 clinical trial of SNS812 for the treatment of the COVID-19 infection. Fespixon is...

Logo
184 Views
Share
bullishOneness Biotech
19 Mar 2022 18:15

Oneness Biotech (4743 TT): Worth of Attention Ahead of Upcoming Key Milestones

The company’s flagship drug Fespixon has $14 billion global market opportunity, while other late-stage pipeline entail visibility in the long-term....

Logo
370 Views
Share
x